| Outcome Measures: |
Primary: Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen, Percentage of subjects achieving a HbA1c ≤ 7.5% and having a reversal from a BBIT to a BOT regimen with treatment of dapagliflozin/saxagliptin or placebo, 24 weeks | Secondary: changes in HbA1c between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in hypoglycaemic events between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in fasting blood glucose between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in daily insulin dose between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in bodyweight between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in body fat content between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in body fat distribution between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in liver fat content between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in intra-nasal insulin-induced brain fMR (functional magnetic resonance) imaging results between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in blood pressure between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in the blood lipid profile between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in microalbuminuria between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in well being and disease perception between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in fear of hypoglycemia between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks | Other: changes in fetuin-A levels between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in adiponectin levels between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in (Interleucin 1?ßß) IL-1ß levels between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in Il-6 levels between groups, treatment of dapagliflozin/saxagliptinn or placebo, 24 weeks|differences in adverse events between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|differences in severe adverse events between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|differences in heart rate between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|differences in ECG parameters between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks|changes in clinical chemistry/haematology parameters between groups, treatment of dapagliflozin/saxagliptin or placebo, 24 weeks
|
